These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 22650448)

  • 21. Follicular lymphoma: 2011 update on diagnosis and management.
    Freedman A
    Am J Hematol; 2011 Sep; 86(9):768-75. PubMed ID: 21850659
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Model-based design of rituximab dosage optimization in follicular non-Hodgkin's lymphoma.
    Ternant D; Cartron G; Hénin E; Tod M; Girard P; Paintaud G
    Br J Clin Pharmacol; 2012 Apr; 73(4):597-605. PubMed ID: 21999172
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 trial of rituximab and bortezomib in patients with relapsed or refractory mantle cell and follicular lymphoma.
    Baiocchi RA; Alinari L; Lustberg ME; Lin TS; Porcu P; Li X; Johnston JS; Byrd JC; Blum KA
    Cancer; 2011 Jun; 117(11):2442-51. PubMed ID: 24048792
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Rituximab and Chemotherapy for Newly Diagnosed Follicular Lymphoma: Real-World Report of Polish Lymphoma Research Group.
    Paszkiewicz-Kozik E; Debowska M; Jakacka N; Kotarska M; Szymanski M; Wisniewski K; Konska A; Jarzembowska M; Drozd-Sokolowska J; Romejko-Jarosinska J; Szumera-Cieckiewicz A; Rymkiewicz G; Ziarkiewicz-Wroblewska B; Lech-Maranda E; Walewski J; Hus I
    Chemotherapy; 2022; 67(4):201-210. PubMed ID: 35249035
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of "watch and wait" in intestinal follicular lymphoma in rituximab era.
    Tari A; Asaoku H; Takata K; Fujimori S; Tanaka S; Fujihara M; Koga T; Yoshino T
    Scand J Gastroenterol; 2016 Mar; 51(3):321-8. PubMed ID: 26382560
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bendamustine plus Rituximab Versus R-CHOP as First-Line Treatment for Patients with Follicular Lymphoma Grade 3A: Evidence from a Multicenter, Retrospective Study.
    Mondello P; Steiner N; Willenbacher W; Cerchione C; Nappi D; Mauro E; Ferrero S; Cuzzocrea S; Mian M
    Oncologist; 2018 Apr; 23(4):454-460. PubMed ID: 29317554
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Rituximab maintenance therapy for follicular lymphoma: no better than watchful waiting.
    Prescrire Int; 2012 Mar; 21(125):62. PubMed ID: 22428182
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Watchful waiting in low-tumor burden follicular lymphoma in the rituximab era: results of an F2-study database.
    Solal-Céligny P; Bellei M; Marcheselli L; Pesce EA; Pileri S; McLaughlin P; Luminari S; Pro B; Montoto S; Ferreri AJ; Deconinck E; Milpied N; Gordon LI; Federico M
    J Clin Oncol; 2012 Nov; 30(31):3848-53. PubMed ID: 23008294
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Influence of the watch and wait strategy on clinical outcomes of patients with follicular lymphoma in the rituximab era.
    Yuda S; Maruyama D; Maeshima AM; Makita S; Kitahara H; Miyamoto KI; Fukuhara S; Munakata W; Suzuki T; Kobayashi Y; Tajima K; Taniguchi H; Tobinai K
    Ann Hematol; 2016 Dec; 95(12):2017-2022. PubMed ID: 27666284
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Rituximab for the treatment of relapsed or refractory stage III or IV follicular non-Hodgkin's lymphoma.
    Boland A; Bagust A; Hockenhull J; Davis H; Chu P; Dickson R
    Health Technol Assess; 2009 Sep; 13 Suppl 2():41-8. PubMed ID: 19804688
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prolonged treatment with rituximab in patients with follicular lymphoma significantly increases event-free survival and response duration compared with the standard weekly x 4 schedule.
    Ghielmini M; Schmitz SF; Cogliatti SB; Pichert G; Hummerjohann J; Waltzer U; Fey MF; Betticher DC; Martinelli G; Peccatori F; Hess U; Zucca E; Stupp R; Kovacsovics T; Helg C; Lohri A; Bargetzi M; Vorobiof D; Cerny T
    Blood; 2004 Jun; 103(12):4416-23. PubMed ID: 14976046
    [TBL] [Abstract][Full Text] [Related]  

  • 32. High-dose therapy with autologous stem cell transplantation versus chemotherapy or immuno-chemotherapy for follicular lymphoma in adults.
    Schaaf M; Reiser M; Borchmann P; Engert A; Skoetz N
    Cochrane Database Syst Rev; 2012 Jan; 1():CD007678. PubMed ID: 22258971
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the University of Iowa/MayoClinic Specialized Program of Research Excellence Molecular Epidemiology Resource.
    Link BK; Maurer MJ; Nowakowski GS; Ansell SM; Macon WR; Syrbu SI; Slager SL; Thompson CA; Inwards DJ; Johnston PB; Colgan JP; Witzig TE; Habermann TM; Cerhan JR
    J Clin Oncol; 2013 Sep; 31(26):3272-8. PubMed ID: 23897955
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Is observation dead in follicular lymphoma? Still appropriate.
    Jacobson CA; Freedman AS
    J Natl Compr Canc Netw; 2015 Mar; 13(3):367-70. PubMed ID: 25736012
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Primary nodal follicular lymphoma with secondary cutaneous manifestations. First-line rituximab monotherapy].
    Koch R; Sander CA
    Hautarzt; 2010 Nov; 61(11):976-9. PubMed ID: 20221574
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Follicular lymphoma: watch and wait is watch and worry.
    Ansell SM
    Lancet Oncol; 2014 Apr; 15(4):368-9. PubMed ID: 24602759
    [No Abstract]   [Full Text] [Related]  

  • 37. R-CHOP, radioimmunotherapy, and maintenance rituximab in untreated follicular lymphoma (SWOG S0801): a single-arm, phase 2, multicentre study.
    Barr PM; Li H; Burack WR; LeBlanc M; Smith SM; Gopal AK; Floyd JD; Persky DO; Press OW; Fisher RI; Friedberg JW
    Lancet Haematol; 2018 Mar; 5(3):e102-e108. PubMed ID: 29396094
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Consolidation treatment with Yttrium-90 ibritumomab tiuxetan after new induction regimen in patients with intermediate- and high-risk follicular lymphoma according to the follicular lymphoma international prognostic index: a multicenter, prospective phase II trial of the Spanish Lymphoma Oncology Group.
    Provencio M; Cruz Mora MÁ; Gómez-Codina J; Quero Blanco C; Llanos M; García-Arroyo FR; de la Cruz L; Gumá Padró J; Delgado Pérez JR; Sánchez A; Alvarez Cabellos R; Rueda A;
    Leuk Lymphoma; 2014 Jan; 55(1):51-5. PubMed ID: 23573825
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Rituximab with or without bevacizumab for the treatment of patients with relapsed follicular lymphoma.
    Hainsworth JD; Greco FA; Raefsky EL; Thompson DS; Lunin S; Reeves J; White L; Quinn R; DeBusk LM; Flinn IW
    Clin Lymphoma Myeloma Leuk; 2014 Aug; 14(4):277-83. PubMed ID: 24679633
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rituximab for follicular lymphoma: watch and wait, watch and worry, or watch and live?
    LeBlanc T; Kamal A; Abernethy A
    Lancet Oncol; 2014 Jun; 15(7):e251-2. PubMed ID: 24872108
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.